Sector News

AbbVie’s $21B buyout puts Pharmacyclics execs in line for $4B payoff

March 24, 2015
Life sciences
Pharmacyclics CEO Robert Duggan would add $3.5 billion to his already substantial wealth, if and when AbbVie’s $21 billion buyout goes through. But considering Duggan’s record, a multibillion-dollar payoff is to be expected. It’s the other executives and directors–who together qualify for more than $575 million–who could inspire M&A envy.
 
COO Mahkam Zanganeh, for instance, would rack up severance of $48 million, provided she’s squeezed out within two years of the merger. That includes compensation for the tax bill she’d have to pay on her windfall. More immediately–and certainly–she’ll reap a hefty $224.6 million for her shares and options, according to an SEC filing about the merger. Not bad for 6 years’ work at the biotech.
 
But that equity payoff also rewards Zanganeh for tagging Pharmacyclics as an investment target for Duggan in the first place, as her official bio points out. And a big chunk of that amount comes from the 428,281 shares Zanganeh already owns–a stake worth almost $119 million in the merger. The remaining millions come from share awards and options that were part of her compensation.
 
Pharmacyclics execs who don’t already own major stakes in the company will still enjoy quite sizable windfalls. CFO Manmeet Soni, for instance, stands to get $29.8 million for his equity, $15 million in cash for his options and $14 million for stock awards. And if he’s in line for a severance payoff almost as big as Zanganeh’s at $46 million, provided he’s terminated or leaves “for good reason,” under the company’s severance policy.
 
And Chief Commercial Officer Shawn Tomasello–who just joined Pharmacyclics last year from Celgene–is up for $28 million in severance herself. Plus almost $29 million for her equity with $26 million of that from options and share awards.
 
The moral of this story? We’d say the point is that M&A pays off for the execs involved. But that’s obvious. The real takeaway? Get a job at Duggan’s next venture.
 
By Tracy Staton
 

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.